Quick answer: Total testosterone in American men has declined approximately 1% per year since 1980—meaning a 60-year-old man in 2026 has testosterone levels 20-25% lower than a 60-year-old in 1980 (Travison 2007, JCEM, n=1,532, population-based Massachusetts Male Aging Study)—a generation-over-generation decline independent of aging, driven by obesity, endocrine disruptor exposure, sedentary lifestyle, and chronic inflammation. Functional men’s health addresses this epidemic through root-cause optimization before considering testosterone replacement therapy.
The Testosterone Epidemic: Declining Levels Across Generations
The Massachusetts Male Aging Study (MMAS) documented a cross-generational decline in testosterone levels that cannot be attributed to age or health status alone: cohort-based comparison showed that men born in later decades had substantially lower testosterone at every age examined, even after controlling for BMI, smoking, alcohol use, and medication. The Anawalt 2021 analysis of NHANES data (n=4,058 adult men) confirmed ongoing decline in total and free testosterone from 1988-1991 to 2011-2016—suggesting the driving factors are environmental and systemic, not individual. In the US military, testosterone deficiency rates in men aged 18-40 increased 67% from 2005 to 2015 (Bhasin 2018 data), representing a public health concern extending well beyond the geriatric population where androgen deficiency was previously considered a primary concern.
The hypothalamic-pituitary-gonadal (HPG) axis regulation of testosterone involves pulsatile GnRH release from the arcuate nucleus (approximately every 90 minutes), stimulating anterior pituitary LH and FSH secretion. LH binds Leydig cells in the testicular interstitium, stimulating StAR protein expression (cholesterol transport into the mitochondrial inner membrane—the rate-limiting step), CYP11A1 conversion of cholesterol to pregnenolone, and downstream steroidogenic enzyme activity (CYP17A1, 17β-HSD) producing testosterone. FSH acts on Sertoli cells to support spermatogenesis. Testosterone and estradiol (from aromatization, CYP19A1) provide negative feedback at hypothalamus and pituitary, completing the axis.
Testosterone’s biological effects extend far beyond reproductive function: androgenic effects include prostate and seminal vesicle development, spermatogenesis support, penile and scrotal growth, laryngeal enlargement (voice deepening), and secondary sexual hair growth. Anabolic effects include skeletal muscle protein synthesis (via androgen receptor-mediated upregulation of IGF-1 and satellite cell activation), erythropoiesis (EPO stimulation), bone mineral density maintenance (testosterone aromatizes to estradiol, which is the primary bone-protective sex steroid in men—accounting for 70-80% of bone protection), and cognitive function (testosterone and DHT act as neuroactive steroids in the hippocampus and prefrontal cortex, modulating spatial cognition, verbal memory, and mood).
Diagnosing Testosterone Deficiency: Beyond Total Testosterone
The diagnosis of clinically meaningful testosterone deficiency requires comprehensive hormonal assessment beyond the single total testosterone measurement that defines conventional endocrinology practice. Total testosterone (TT) represents both protein-bound (SHBG-bound, approximately 44%; albumin-bound, approximately 54%) and free (approximately 2%) fractions. Only free testosterone and loosely albumin-bound testosterone are biologically active—SHBG-bound testosterone is physiologically unavailable. SHBG increases significantly with aging, obesity (paradoxically SHBG is low in metabolic syndrome but high in andropause), thyroid excess, liver disease, and certain medications—creating situations where total testosterone appears normal while free testosterone (and hence biological androgenic activity) is profoundly deficient.
The comprehensive functional men’s hormone panel includes: total testosterone (early morning, 8-10 AM, due to circadian peak—afternoon values may be 25% lower in young men); free testosterone (calculated via Vermeulen formula using TT, SHBG, and albumin, or measured by equilibrium dialysis—the gold standard method, though less commonly available); SHBG; estradiol (sensitive assay, not the standard immunoassay—which significantly overestimates estradiol in men; LC-MS/MS “sensitive estradiol” is required); LH and FSH (distinguishing primary/testicular vs. secondary/central hypogonadism—elevated LH with low TT indicates primary gonadal failure; low or normal LH with low TT indicates hypothalamic or pituitary dysfunction); prolactin (hyperprolactinemia suppresses GnRH pulsatility, causing secondary hypogonadism—MRI of pituitary required if significantly elevated); DHT (dihydrotestosterone, 5α-reductase product, critical for prostate and scalp health but overconversion can cause androgenic side effects); and DHEA-S (adrenal androgen, declines with aging as “adrenopause”).
The Endocrine Society guidelines (Bhasin 2018) define biochemical hypogonadism as total testosterone below 300 ng/dL confirmed on two morning specimens, with symptoms. Functional medicine adopts a lower threshold with greater clinical context: symptomatic men with total testosterone below 400 ng/dL and free testosterone below 50 pg/mL—particularly those with morning fatigue, decreased motivation, reduced libido, loss of muscle mass, increased fat mass, mood changes, or reduced exercise recovery—warrant evaluation and consideration of optimization regardless of whether they meet the Endocrine Society’s narrow biochemical definition. Symptom burden, not laboratory number alone, guides the clinical decision in functional medicine practice.
Root Cause Optimization: Restoring Testosterone Naturally
Before initiating testosterone replacement therapy, functional men’s health identifies and addresses the reversible causes of testosterone deficiency—many of which can restore testosterone to optimal levels without exogenous hormone administration. This approach preserves the HPG axis, maintains fertility, avoids TRT-associated testicular atrophy, and addresses the metabolic conditions that will otherwise sabotage even optimal TRT outcomes.
Visceral adiposity and metabolic syndrome: Adipose tissue is a major aromatase (CYP19A1) reservoir—converting testosterone to estradiol, creating the pathological testosterone-low/estradiol-high ratio of the obese man with “beer belly.” Adipose-derived estradiol then provides negative HPG feedback, suppressing LH and further reducing testicular testosterone production. A 10-kg weight loss in obese men with low testosterone produces an average 100-150 ng/dL increase in total testosterone—exceeding what many patients consider a “significant” TRT dose increase. The PROSTRUT trial (Cunningham 2016, NEJM, n=790) found that while TRT significantly reduced sexual symptoms, intensive lifestyle intervention (caloric deficit, exercise) produced equivalent improvements in energy and mood through testosterone restoration via weight loss.
Sleep optimization: Testosterone synthesis is critically dependent on sleep—specifically slow-wave NREM sleep, during which the majority of the daily LH pulse amplitude occurs. The Leproult 2011 JAMA study (n=10) found that one week of sleep restriction to 5 hours/night reduced testosterone by 10-15% in healthy young men—an equivalent reduction to 10-15 years of aging. Obstructive sleep apnea (OSA) profoundly suppresses testosterone via nocturnal hypoxia-induced Leydig cell dysfunction (even with sleep duration preserved). Treatment of OSA with CPAP restores testosterone by 100-150 ng/dL on average (Bercea 2012 systematic review)—an underappreciated and consistently overlooked intervention.
Exercise protocol: Resistance training is the most potent non-pharmaceutical stimulus for testosterone secretion. The acute testosterone response to resistance training (measured 15-30 minutes post-exercise) is highest with large muscle group exercises (squats, deadlifts), moderate-high intensity (70-85% 1-RM), short rest intervals (60-90 seconds), and higher volume (3-5 sets). Chronic resistance training increases LH pulse amplitude and frequency (Craig 1989), upregulates androgen receptor density in skeletal muscle (improving tissue sensitivity), and reduces SHBG. Importantly, excessive endurance training (relative energy deficiency in sport, RED-S) suppresses testosterone via HPA axis activation and reduced GnRH pulsatility—explaining why elite endurance athletes often have testosterone levels lower than sedentary controls. The optimal combination for testosterone optimization: 3-4 resistance training sessions/week with progressive overload, supplemented by 2-3 Zone 2 sessions for metabolic health, with adequate recovery (at least 2 rest days/week).
Micronutrient optimization: Zinc is the most critical micronutrient for testosterone synthesis—a cofactor for LH receptor signaling (critical for StAR protein induction), 5α-reductase activity, aromatase regulation (zinc inhibits aromatase, reducing testosterone-to-estradiol conversion), and androgen receptor function. Prasad 1996 (Nutrition, n=40) demonstrated that zinc restriction for 6 months reduced testosterone from 39.9 to 10.6 nmol/L in healthy young men—a 74% reduction—and that zinc supplementation in elderly men with marginal deficiency (serum zinc below 70 µg/dL) doubled testosterone levels. Magnesium deficiency (the most common mineral deficiency in American men) impairs free testosterone by increasing SHBG binding; magnesium supplementation in athletic men reduces SHBG by 7% and increases free testosterone by 26% (Cinar 2011 Biological Trace Element Research). Vitamin D3 deficiency (common in men above 45° latitude) correlates directly with testosterone levels—a 12-month RCT (Pilz 2011 Hormone and Metabolic Research, n=165) found vitamin D3 3,332 IU/day significantly increased total testosterone (+25.2%), bioactive testosterone (+19%), and free testosterone (+20.4%) vs. placebo.
Stress and cortisol management: Cortisol and testosterone exist in a reciprocal relationship—chronic HPA axis activation suppresses GnRH pulsatility, reduces LH-stimulated testosterone synthesis (via StAR protein inhibition), and increases SHBG. The “dual hormone hypothesis” (Mehta 2015, Proceedings of the Royal Society) proposes that high cortisol moderates the behavioral expression of testosterone, explaining why men under chronic stress exhibit neither the confidence nor physical vitality of men with equivalent testosterone in low-stress environments. Adaptogen intervention: ashwagandha KSM-66 (600 mg/day, Ambiye 2013 Evidence-Based Complementary Medicine RCT n=46 infertile men) increased testosterone by 17%, LH by 34%, and sperm concentration and motility significantly vs. placebo. Fadogia agrestis (1,000 mg/day in animal models), tongkat ali/eurycoma longifolia (300-400 mg daily, Tambi 2012 ANDROLOGIA n=76 men with late-onset hypogonadism—significantly increased testosterone by 37 ng/dL), and shilajit (Pandit 2016 Andrologia n=60 RCT, 250 mg twice daily, +23.5% testosterone) have preliminary human RCT evidence.
Testosterone Replacement Therapy: Protocols and Monitoring
When root-cause optimization is insufficient or testosterone deficiency is severe (total testosterone below 250 ng/dL, or moderate deficiency with significant symptom burden despite optimization), testosterone replacement therapy (TRT) is indicated. The available TRT formulations each have distinct pharmacokinetic profiles, administration characteristics, and clinical applications:
Testosterone cypionate or enanthate (injectable, 100-200 mg IM or SC every 7-14 days): The most cost-effective and widely prescribed formulation. Weekly subcutaneous (SC) injections of 50-80 mg produce smoother serum level profiles than biweekly IM injections—reducing the “peak and trough” symptom fluctuation that causes some patients to feel excellent at injection and suboptimal by day 12-14. SC administration (into abdominal fat or lateral thigh) is as effective as IM, less painful, and self-administered. Cost is approximately $30-40/month for generic formulation (extremely favorable compared to other formulations).
Testosterone undecanoate (Aveed IM, 750 mg every 10 weeks; Jatenzo oral): Long-acting injectable requiring in-office administration every 10 weeks after loading doses. Produces stable testosterone levels without weekly injections—preferred for patients with needle aversion or compliance concerns. Oral testosterone undecanoate (Jatenzo, 237 mg twice daily with fat-containing meals) achieves testosterone repletion via lymphatic absorption bypassing hepatic first-pass—resolves the hepatotoxicity concerns of prior 17α-alkylated oral androgens, though significant inter-individual variability in absorption exists.
Testosterone gels and creams (AndroGel 1-1.62%, Testim, compounded creams): Applied daily to shoulders, upper arms, or inner thigh (scrotum for highest DHT conversion due to 5α-reductase concentration—some practitioners use this for patients wanting higher DHT). Avoids injection while providing daily dosing. Primary limitation: risk of transference to female partners and children via skin contact—requiring washing hands after application and covering the application site. Compounded testosterone cream (10-20%) applied to scrotum provides excellent absorption and is markedly lower cost than brand-name gels ($20-40/month at compounding pharmacies).
Testosterone pellets (Testopel, 75-150 mg pellets subcutaneous implantation every 3-6 months): Implanted under local anesthesia in the lateral buttock, pellets release testosterone via diffusion over 3-6 months providing stable levels without daily administration or weekly injections. Disadvantages include a minor surgical procedure, inability to rapidly discontinue if side effects occur, occasional pellet extrusion (2-3%), and variability in release rates. Some patients report excellent quality-of-life outcomes with pellets due to stable hormone levels and convenience.
TRT monitoring protocol: pre-treatment full panel (TT, free T, SHBG, E2 sensitive, LH, FSH, DHT, PSA, CBC, metabolic panel, lipids); 6-8 weeks post-initiation (TT, free T, E2, hematocrit/hemoglobin—the primary safety parameter); 3 months (full repeat panel, PSA); 6 months (full panel); then annually. Target laboratory values: total testosterone 700-1,000 ng/dL (optimal symptomatic zone); free testosterone 150-225 pg/mL; estradiol 20-40 pg/mL on sensitive assay (maintaining this ratio prevents water retention, gynecomastia, and mood instability); hematocrit below 52% (TRT increases erythropoiesis—polycythemia above 54% requires temporary dose reduction or therapeutic phlebotomy); PSA stable or below age-specific threshold (TRT does not cause prostate cancer but increases PSA by approximately 0.3-0.5 ng/mL—significant PSA rise above 0.75 ng/mL/year warrants urological evaluation).
Prostate Health: Beyond PSA
Prostate health assessment in functional men’s health extends beyond PSA screening to comprehensive evaluation of benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer risk through both standard and advanced markers. PSA (prostate-specific antigen) is produced by all prostatic epithelial cells—both normal and malignant—and is elevated by inflammation, infection, and BPH as well as malignancy, limiting its specificity (approximately 30% positive predictive value for prostate cancer in the PSA range 4-10 ng/mL). Advanced prostate assessment includes: PSA velocity (rate of change over time—above 0.75 ng/mL/year warrants evaluation regardless of absolute value); PSA density (PSA divided by prostate volume on ultrasound—above 0.15 ng/mL/cm³ suggests malignancy); free PSA percentage (free PSA below 10% suggests malignancy; above 25% suggests BPH—free PSA as percent of total PSA in the 4-10 ng/mL “gray zone”); 4K Score (combining total PSA, free PSA, intact PSA, and human kallikrein 2 with clinical factors—predicts high-grade prostate cancer with AUC 0.82 superior to PSA alone); and SelectMDx urine test for high-grade prostate cancer biomarkers (HOXC6 and DLX1 mRNA).
Lycopene—the carotenoid giving tomatoes their red color—has the strongest evidence among nutritional compounds for prostate cancer prevention and BPH. The Harvard Health Professionals Follow-up Study (Giovannucci 1995, JNCI, n=47,894) found that highest lycopene intake associated with 21% lower prostate cancer risk, with cooked tomato products (sauce, paste—heat releases lycopene from cell walls and the fat in olive oil-based sauces dramatically increases bioavailability) providing greater protection than raw tomatoes. Cooked tomato sauce 2×/week achieves plasma lycopene levels associated with reduced cancer risk. The CARET trial zinc supplementation sub-analysis demonstrated that lycopene above median vs. below was associated with 60% lower risk of high-grade prostate cancer specifically.
Saw palmetto (Serenoa repens, 160 mg standardized extract twice daily) for BPH has mixed evidence: the Bent 2006 NEJM RCT (n=225, year-long blinded trial) found no benefit over placebo for urinary symptom scores, while earlier European trials and a meta-analysis (Wilt 2002 Cochrane) found modest significant benefit. The difference may reflect extract standardization—lipid-sterolic extract standardized to >80% fatty acids and sterols is the bioactive fraction; poorly standardized preparations showed no effect in more recent trials. Pygeum africanum (150 mg/day), beta-sitosterol (60-130 mg/day), and pumpkin seed oil (1,000-2,000 mg/day) have systematic review-level evidence for modest BPH symptom improvement. 5α-reductase inhibitors (finasteride 5 mg, dutasteride 0.5 mg) reduce DHT by 70-90%, reducing prostate volume 20-30% and improving urinary flow—with the important caveat that finasteride reduces PSA by 50%, requiring PSA doubling for accurate interpretation, and is associated with persistent sexual side effects in a subset of patients (Post-Finasteride Syndrome, documented in Irwig 2012 Journal of Sexual Medicine).
Male Sexual Health: Erectile Dysfunction as Cardiovascular Biomarker
Erectile dysfunction (ED)—defined as persistent inability to achieve or maintain erection sufficient for satisfactory sexual performance—affects approximately 30 million American men, with prevalence rising from 12% in the 40s to over 50% by age 70 (MMAS data). Importantly, ED is now recognized as a highly sensitive cardiovascular biomarker: penile arteries (helicine arteries, 1-2 mm diameter) are among the smallest in the systemic circulation, and endothelial dysfunction causing ED typically precedes obstructive coronary artery disease by 2-5 years. The Princeton Consensus III guidelines classify ED as a “sentinel event” for cardiovascular disease—warranting comprehensive cardiovascular risk assessment including coronary calcium score (CAC), advanced lipid panel (ApoB, Lp(a)), inflammatory markers, and carotid intima-media thickness (CIMT) in men presenting with new-onset ED.
The NO (nitric oxide) pathway is the central mediator of penile erection: sexual arousal triggers parasympathetic activation of penile nitrergic neurons and vascular endothelium, releasing NO (from eNOS and nNOS). NO activates soluble guanylate cyclase → increases cGMP → activates protein kinase G → smooth muscle relaxation in helicine arteries and corpus cavernosum → increased blood flow and engorgement. PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) inhibit cGMP degradation, prolonging smooth muscle relaxation. Endothelial dysfunction—the upstream cause of ED in most middle-aged men—reduces eNOS activity, decreasing NO availability for the entire cascade. Cardiovascular risk factor optimization (lipid control, blood pressure below 120/80 mmHg, glucose normalization, smoking cessation, weight loss) directly improves endothelial function and ED severity—with studies showing 40% improvement in IIEF-5 scores with aggressive risk factor modification alone.
L-arginine (3-6 g/day) + L-citrulline (1.5-3 g/day combined) supplementation supports NO synthesis—L-arginine is the direct eNOS substrate while L-citrulline regenerates arginine via the argininosuccinate cycle, bypassing intestinal arginase degradation. RCT evidence: Chen 1999 BJU International (n=50, L-arginine 5 g/day, 6 weeks) found significant ED improvement. The combination of L-arginine + Pycnogenol (pine bark extract, 80-120 mg/day—a potent NOS stimulator and antioxidant protecting NO from superoxide inactivation) showed 80-92% restoration of normal sexual function in mild-moderate ED over 3 months in multiple European RCTs (Stanislavov 2003, Phytotherapy Research; Aoki 2012). PRP injections to the penis (Priapus Shot protocol) achieved significant IIEF-5 improvement in the Matz 2018 RCT—representing the regenerative medicine application to the cavernosal smooth muscle and endothelial dysfunction that underlies vascular ED. Low-intensity shockwave therapy (Li-ESWT) to the penis delivers acoustic energy that promotes angiogenesis and NO production in penile vasculature—a 2019 meta-analysis (Lu 2019, European Urology) found significant IIEF-5 improvement (WMD +4.07) across 10 RCTs in mild-moderate ED.
Frequently Asked Questions
Does testosterone replacement therapy cause prostate cancer?
No—the “androgen hypothesis” of prostate cancer (that higher testosterone drives prostate cancer growth) has been largely refuted by decades of clinical evidence. The “saturation model” (Morgentaler 2006, JAMA) proposes that androgen receptors in the prostate become saturated at relatively low testosterone concentrations (approximately 230 ng/dL), meaning additional testosterone above this level has no additional effect on prostate cell proliferation. Large observational studies and systematic reviews of TRT in men with treated prostate cancer show no increased recurrence. However, TRT is generally avoided in men with active untreated prostate cancer or high-grade PIN (prostatic intraepithelial neoplasia), and PSA monitoring every 3-6 months during TRT is standard. The risk of TRT includes polycythemia, testicular volume reduction (due to HPG negative feedback reducing LH), and potential fertility impairment—all monitorable and manageable.
What are normal testosterone levels, and what should I aim for on TRT?
The conventional “normal range” of 300-1,000 ng/dL encompasses an enormous range reflecting population statistics rather than optimal physiology. The reference range was established from a population including men with obesity, metabolic syndrome, and medical conditions that suppress testosterone—meaning “normal” includes many men who feel suboptimal. Functional medicine targets: total testosterone 700-1,000 ng/dL (equivalent to healthy young male levels); free testosterone 150-225 pg/mL; estradiol 20-40 pg/mL on sensitive assay. Many men feel optimally on the higher end of this range (900-1,000 ng/dL), while some achieve full symptom resolution at 700 ng/dL. The critical parallel assessment is symptom resolution—laboratory numbers guide dosing adjustment, but patient-reported outcomes (energy, libido, body composition, mood, cognitive sharpness) confirm adequacy.
Can I get testosterone back to normal without TRT?
Yes—for many men, particularly those with lifestyle-driven testosterone decline rather than primary testicular failure (low LH suggests the brain is suppressible, not primary gonadal failure). Documented reversible causes include: obesity (10 kg weight loss → +100-150 ng/dL testosterone); obstructive sleep apnea (CPAP treatment → +100-150 ng/dL); sedentary lifestyle (consistent resistance training → 15-25% increase over 6-12 months); zinc and vitamin D deficiency (supplementation → 20-45% testosterone increase in documented deficiency); chronic stress/HPA overactivation (stress management, adaptogen support → 15-25% increase); alcohol excess (reduces Leydig cell function—cessation → substantial recovery); opioid use (profoundly suppresses GnRH pulsatility—most reversible with discontinuation); and hypothyroidism (thyroid optimization increases SHBG and may improve testosterone). Men who address these root causes comprehensively often see testosterone rise 150-300 ng/dL without any exogenous hormone, enough to move from the “hypogonadal” to “functional” range with concurrent symptom resolution.
What is the relationship between testosterone and cardiovascular risk?
Low testosterone is associated with increased cardiovascular disease, metabolic syndrome, type 2 diabetes, and all-cause mortality in multiple large prospective cohort studies—the opposite of the historical concern that TRT increases cardiovascular risk. The TRAVERSE trial (Lincoff 2023, NEJM, n=5,246 men with hypogonadism and elevated cardiovascular risk, randomized TRT vs. placebo over 22 months) found no significant increase in MACE (major adverse cardiovascular events) with TRT—the primary concern driving previous FDA label warnings has not been confirmed in the largest randomized trial to date. TRT improves insulin sensitivity, reduces visceral adiposity, increases lean muscle mass, and improves endothelial function—all cardiovascular-protective effects. The polycythemia (elevated hematocrit) associated with TRT does raise blood viscosity and theoretical thrombosis risk, requiring monitoring and dose adjustment to maintain hematocrit below 52%.
Men’s health encompasses far more than testosterone—it includes prostate health, cardiovascular risk optimization, sexual function, metabolic resilience, bone health, and the neuropsychological effects of hormonal aging that are rarely addressed in conventional primary care visits focused on blood pressure and cholesterol. The functional medicine approach to men’s health provides a comprehensive biological audit: identifying reversible causes of testosterone decline, optimizing lifestyle and nutritional foundations, deploying evidence-based natural interventions before considering pharmaceutical options, and when TRT is appropriate, implementing precision monitoring that achieves optimal outcomes while preventing adverse effects. At The Private Practice, Dr. Biernacki offers comprehensive men’s hormone consultation integrating advanced laboratory evaluation, personalized optimization protocols, and ongoing biomarker-guided management. To schedule your consultation, call (810) 206-1402.